[1] SIEGEL R, MILLER K, WAGLE N S, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73: 17-48. doi:  10.3322/caac.21763
[2] ZHANG X Y, QIU H, LI C S, et al. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer[J]. Biosci Trends, 2021, 15(5): 283-298. doi:  10.5582/bst.2021.01318
[3] GREENLEE H, DUPONT-REYES M J, BALNEAVES L G, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment[J]. CA Cancer J Clin, 2017, 67(3): 194-232. doi:  10.3322/caac.21397
[4] CHEN M H, GU Y Y, ZHANG A L, et al. Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer[J]. Pharmacol Res, 2021, 171: 105778. doi:  10.1016/j.phrs.2021.105778
[5] 李梢. 基于生物网络调控的方剂研究模式与实践[J]. 中西医结合学报, 2007, 5(5): 489-493.
[6] 林玲, 吴勤研, 宋熙薇. 基于网络药理学的康艾注射液抗非小细胞肺癌作用机制分析[J]. 药学与临床研究, 2021, 29(2): 86-91.
[7] WANG Y X, ZHANG S, LI F C, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics[J]. Nucleic Acids Res, 2020, 48(D1): D1031-D1041.
[8] 李华华, 杨峰, 裴俊文, 等. 杨峰教授在清热解毒理论指导下运用复方苦参注射液治疗恶性肿瘤经验[J]. 中医研究, 2021, 34(7): 74-76.
[9] 李佳鑫, 王冰, 于淼. 基于“扶正祛邪”治则的中药抗肿瘤作用机制的研究进展[J]. 中草药, 2021, 52(18): 5751-5757.
[10] LI J J, ZHANG X, SHEN X C, et al. Phytochemistry and biological properties of isoprenoid flavonoids from Sophora flavescens Ait[J]. Fitoterapia, 2020, 143: 104556. doi:  10.1016/j.fitote.2020.104556
[11] MASUDA H, ZHANG D W, BARTHOLOMEUSZ C, et al. Role of epidermal growth factor receptor in breast cancer[J]. Breast Cancer Res Treat, 2012, 136(2): 331-345. doi:  10.1007/s10549-012-2289-9
[12] BURNESS M L, GRUSHKO T A, OLOPADE O I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?[J]. Cancer J, 2010, 16(1): 23-32. doi:  10.1097/PPO.0b013e3181d24fc1
[13] NAKAI K, HUNG M C, YAMAGUCHI H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer[J]. Am J Cancer Res,2016,6(8):1609-1623.
[14] LI W, HOU J Z, NIU J, et al. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation[J]. Cell Commun Signal, 2018, 16(1): 82. doi:  10.1186/s12964-018-0295-1
[15] GAO F, ALWHAIBI A, SABBINENI H, et al. Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis[J]. Cancer Lett, 2017, 402: 177-189. doi:  10.1016/j.canlet.2017.05.028
[16] CHEN K, JIAO X M, ROCCO A D, et al. Endogenous cyclin D1 promotes the rate of onset and magnitude of mitogenic signaling via Akt1 Ser473 phosphorylation[J]. Cell Rep, 2020, 32(11): 108151. doi:  10.1016/j.celrep.2020.108151
[17] GEELEN C T, SAVAS P, TEO Z L, et al. Clinical implications of prospective genomic profiling of metastatic breast cancer patients[J]. Breast Cancer Res, 2020, 22(1): 1-13. doi:  10.1186/s13058-019-1178-0
[18] DOSSOU A S, BASU A. The emerging roles of mTORC1 in macromanaging autophagy[J]. Cancers, 2019, 11(10): 1422. doi:  10.3390/cancers11101422
[19] SCHMID P, ABRAHAM J, CHAN S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial[J]. J Clin Oncol, 2020, 38(5): 423-433. doi:  10.1200/JCO.19.00368
[20] LI C W, XIA W Y, LIM S O, et al. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation[J]. Cancer Res, 2016, 76(6): 1451-1462. doi:  10.1158/0008-5472.CAN-15-1941
[21] LIU H, RADISKY D C, NELSON C M, et al. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2[J]. Proc Natl Acad Sci U S A, 2006, 103(11): 4134-4139. doi:  10.1073/pnas.0511342103
[22] HANKER A B, KAKLAMANI V, ARTEAGA C L. Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors[J]. Cancer Discov, 2019, 9(4): 482-491. doi:  10.1158/2159-8290.CD-18-1175
[23] VERNIERI C, CORTI F, NICHETTI F, et al. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications[J]. Breast Cancer Res, 2020, 22(1): 33. doi:  10.1186/s13058-020-01271-0
[24] HYMAN D M, SMYTH L M, DONOGHUE M T A, et al. AKT inhibition in solid tumors with AKT1 mutations[J]. J Clin Oncol, 2017, 35(20): 2251-2259. doi:  10.1200/JCO.2017.73.0143
[25] KIM S B, DENT R, IM S A, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2017, 18(10): 1360-1372. doi:  10.1016/S1470-2045(17)30450-3
[26] RAO G H, PIEROBON M, KIM I K, et al. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations[J]. Sci Rep, 2017, 7(1): 7066. doi:  10.1038/s41598-017-06128-9
[27] LEI J T, GOU X X, SEKER S, et al. ESR1 alterations and metastasis in estrogen receptor positive breast cancer[J]. J Cancer Metastasis Treat, 2019, 5: 38.
[28] JESELSOHN R, BUCHWALTER G, ANGELIS C D, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer[J]. Nat Rev Clin Oncol, 2015, 12(10): 573-583. doi:  10.1038/nrclinonc.2015.117
[29] HICKEY T E, SELTH L A, CHIA K M, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer[J]. Nat Med, 2021, 27(2): 310-320. doi:  10.1038/s41591-020-01168-7
[30] YU L H, YU Q H, XU C C, et al. The expression of androgen receptor in triple-negative breast cancer and the effect of a traditional Chinese medicine formula on disease-free survival[J]. Gland Surg, 2022, 11(11): 1772-1783. doi:  10.21037/gs-22-508